AJ303 is a novel compound under development for the treatment of idiopathic pulmonary fibrosis (IPF). It decreased IPF-related inflammatory cytokines, such as IL-6, MCP1, and GM-CSF in vitro, that delays the progression of pulmonary fibrosis in bleomycin-induced pulmonary injury model in mice.
AJ303 has a favorable plasma to pulmonary ratio of tissue distribution after oral administration. Its potential efficacy in treating patients with IPF will be investigated clinically in 2021.
- 60% 60%
- 40% 40%
- 30% 30%
- 15% 15%
- 10% 10%
We look forward to further discussions with you.
Please fill out the form, and we will get right back to you.